Details

Autor(en) / Beteiligte

• Al-Naqqash, Manwar
• Castañeda-Hernández, Gilberto
• Chiang, Shao-Chin
• Ibnshamsah, Fahad
• Reinert, Tomás
• Rifkin, Robert M
• Morsi, Waleed El

Titel

Plain language review: what are biosimilar medicines and how can they be used to treat people with cancer?

Ist Teil von

• Future oncology (London, England), 2024-03, Vol.20 (9), p.481-491

Ort / Verlag

England: Future Medicine Ltd

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• The aim of this plain language review article is to help you to understand biosimilar medicines (called biosimilars) by giving a summary of biologic medicines and biosimilars. It is based on the experience of an international panel of physicians with expertise on biosimilars who discussed and agreed on the topics and information included in this review article. Biologic medicines are medicines that come from living organisms such as bacteria and animal or plant cells. Biosimilars are a group of approved biologic medicines that are similar to original biologic medicines that are already available. This review explains how biosimilars are developed and approved, and how they are used to treat people with cancer. It also answers some common important questions people with cancer might have when taking biosimilars. The purpose of this plain language review is to help you to understand the findings from recent research. This review reports information from peer-reviewed literature and other sources available in the public domain (e.g., regulatory documents or product information labels). The findings may differ from those of other review articles. Health professionals should make treatment decisions based on all available evidence.